Abstract: Objective To compare the efficacy and toxicity of gemcitabine plus cisplatin between the elderly patients with advanced non-small-cell lung cancer and the younger.Methods 35 elderly advanced non-small-cell lung cancer patients received chemotherapy with gemcitabine and cisplatin every 3weeks and the 35 younger patients as a comparison.The efficacy and toxicity were observed.Results Compared with the younger patients, the elderly have more co-morbidity and lower KPS score and received fewer cycles of chemotherapy.The response rate, median survival time, and 1-year survival rate were 45.7%, 9.0 months, 38.2% in the elderly and 51.4%, 9.2 months, 40.6% in the younger respectivety.There were no statistical significance between two groups.The toxicity between two group have no statistical significance.Conclusions For the elderly patients with non small cell lung cancer, gemcitabine plus cisplatin every 3 weeks were a safe and effective selection.